Portal de Periódicos da CAPES

A cost–effectiveness analysis of Japanese encephalitis vaccine in Cambodia

2010; Elsevier BV; Volume: 28; Issue: 29 Linguagem: Inglês

10.1016/j.vaccine.2010.04.086

1873-2518

Sok Touch, Chutima Suraratdecha, Chham Samnang, Heng Seng, Lauren Gazley, Chea Huch, Sovann Ly, Chab Seak Chhay, Sann Chan Soeung,

Viral Infections and Outbreaks Research

This study aimed to evaluate the cost and effectiveness of introducing a live, attenuated vaccine (SA 14-14-2) against Japanese encephalitis (JE) into the immunization program. The study demonstrated that SA 14-14-2 immunization is cost–effective in controlling JE in Cambodia compared to no vaccination. Averting one disability-adjusted life year, from a societal perspective, through the introduction of SA 14-14-2 through routine immunization, or a combination of routine immunization plus a campaign targeting children 1–5 or 1–10 years of age, costs US$22, US$34 and US$53, respectively. Sensitivity analyses confirmed that there was a high probability of SA 14-14-2 immunization being cost–effective under conditions of uncertainty.